Effect of Cisatracurium Versus Atracurium on Intraocular Pressure in Patients Underwent General Anesthesia

This study has been completed.
Information provided by:
Isfahan University of Medical Sciences
ClinicalTrials.gov Identifier:
First received: January 10, 2011
Last updated: NA
Last verified: July 2009
History: No changes posted
The purpose of this study is to determine which drug makes lower intraocular pressure

Condition Intervention Phase
Intraocular Pressure
Drug: atracurium
Drug: cisatracurium
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Official Title: Study of Effects of Cisatracurium and Atracurium on Intraocular Pressure

Resource links provided by NLM:

Further study details as provided by Isfahan University of Medical Sciences:

Primary Outcome Measures:
  • intraocular pressure [ Time Frame: at 2 minutes after intubation ] [ Designated as safety issue: Yes ]
    determining intraocular pressure in atracurium and cisatracurium groups

Secondary Outcome Measures:
  • systolic blood pressure [ Time Frame: at 2 minutes after intubation ] [ Designated as safety issue: Yes ]
    identification of systolic blood pressure in atracurium and cisatracurium groups

Enrollment: 90
Study Start Date: July 2009
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Patients who underwent general anesthesia received atracurium
Drug: atracurium
atracurium, Drop,0.5 mg/kg, one time, one day
Patients who underwent general anesthesia received cisatracurium
Drug: cisatracurium
cisatracurium, drop,0.15mg/kg,one time, one day

Detailed Description:
Increase in intraocular pressure (IOP) following tracheal intubation during general anesthesia can be troublesome. The investigators compared the influence of cisatracurium and atracurium on IOP in patients undergoing general anesthesia.

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

ASA class of I or II baseline IOP of lower than 20 mmHg stable hemodynamics no history of ophthalmic diseases not using drugs affecting IOP (e.g. anticholinergics, sympathomimetics) no contraindication for atracurium or cisatracurium administration.

Exclusion Criteria:

difficulty in mask ventilation or in tracheal intubation end expiratory CO2 of below 35 mmHg or over 45 mmHg O2 saturation of below 90%

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01273831

Iran, Islamic Republic of
Al-zahra university hospital
Isfahan, Iran, Islamic Republic of
Sponsors and Collaborators
Isfahan University of Medical Sciences
Study Chair: Mitra Jabalameri, A.Professor Associate Professor,Anesthesiology department
  More Information

Additional Information:
No publications provided

Responsible Party: Dr. Alireza Yousefy/Associate Professor of Medical Education, Isfahan University of Medical Sciences
ClinicalTrials.gov Identifier: NCT01273831     History of Changes
Other Study ID Numbers: ASD-1213-10 
Study First Received: January 10, 2011
Last Updated: January 10, 2011
Health Authority: Iran: Ministry of Health

Keywords provided by Isfahan University of Medical Sciences:
intraocular pressure, anesthesia,cisatracurium,atracurium.

Additional relevant MeSH terms:
Central Nervous System Agents
Central Nervous System Depressants
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Neuromuscular Agents
Neuromuscular Blocking Agents
Neuromuscular Nondepolarizing Agents
Neurotransmitter Agents
Nicotinic Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on February 04, 2016